Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Posted 27 Mar 2026
Dr Lisa Devine discusses efficacy and safety outcomes from a noninferiority trial comparing cardiovascular outcomes with tirzepatide versus dulaglutide in people with type 2 diabetes and atherosclerotic cardiovascular disease.
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page